Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 10,36 € (+41,53%). La mediana è 10,36 € (+41,53%).
| Acquista |
10 |
| Mantieni |
1 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
Xeris Biopharma outlines growth plan at H.C. Wainwright conference
Xeris Biopharma presented its strategic vision, emphasizing growth from Recorlev and a planned phase-3 study for XP8121 in hypothyroidism with gastrointestinal absorption disorders. The company expects revenue growth of around 40% year over year and reports gross margins of about 85% as well as positive adjusted EBITDA in the prior year. Market potential is cited at $1–3 billion for XP8121 and about $1 billion for Recorlev; commercialization is to be driven by expanded sales activities and clinician training. Xeris stresses a self-funded business model but sees competitive pressure in an evolving market. » Altro su de.investing.com
Xeris Pharmaceuticals reaches 52-week high at $8.02 after strong quarterly results and patent
Xeris Pharmaceuticals stock rose to a 52-week high of $8.02 with a market capitalization of about $1.28 billion; however, technical indicators show an overbought level. In Q2 2025 Xeris beat EPS expectations (-$0.01 vs. -$0.03) and reported revenue of $71.5 million, supported by revenue growth of 35.6% year over year. Xeris Biopharma Holdings also received a new patent for Recorlev through March 2040, and H.C. Wainwright initiated coverage with a buy rating and a $10.00 price target. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 80,7 Mln | 32,96% |
| Utile lordo | 69,74 Mln | 44,38% |
| Utile netto | -27,25 Mln | 1565,96% |
| EBITDA | -18,51 Mln | 353,80% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 1,29 Mld € |
Numero di azioni | 172,64 Mln |
Massimo/minimo a 52 settimane | 8,70 € - 4,53 € |
| Dividendi | No |
Beta | 0,85 |
Rapporto P/E | -89,39 |
Rapporto PEG | 0,01 |
Rapporto P/B | -154,11 |
Rapporto P/S | 4,47 |
Profilo aziendale
Xeris Biopharma Holdings, Inc. ist ein biopharmazeutisches Unternehmen, das sich mit der Entwicklung und Vermarktung von Therapien für Patientengruppen in der Endokrinologie, Neurologie und Gastroenterologie befasst. Das Unternehmen vermarktet Gvoke, ein gebrauchsfertiges flüssiges Glukagon zur Behandlung von schwerer Hypoglykämie, und Keveyis, eine Therapie zur Behandlung von hyperkaliämischen, hypokaliämischen und verwandten Varianten der primären periodischen Paralyse, sowie Recorlev, einen Cortisol-Synthesehemmer, der sich zur Behandlung der endogenen Hyperkortisolämie bei erwachsenen Patienten mit Cushing-Syndrom bewährt hat. Darüber hinaus verfügt das Unternehmen über eine Pipeline von Entwicklungsprogrammen zur Erweiterung der vermarkteten Produkte auf neue Indikationen und Verwendungszwecke sowie zur Entwicklung neuer Produkte unter Verwendung der firmeneigenen Formulierungstechnologie-Plattformen XeriSol und XeriJect. Das Unternehmen wurde im Jahr 2005 gegründet und hat seinen Hauptsitz in Chicago, Illinois.
| Nome | Xeris Pharmaceuticals Aktie |
| CEO | John Shannon |
| Sede centrale | Chicago,
il Stati Uniti |
| Sito web | |
| Industria | Prodotti chimici |
| Quotazione in borsa | 21/06/2018 |
| Dipendenti | 435 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | XERS |
London Stock Exchange | 0A8E.L |
Frankfurt | 2B30.F |
Düsseldorf | 2B30.DU |
London | 0A8E.L |
München | 2B30.MU |
Scopri gli asset
Gli azionisti di Xeris Pharmaceuticals Aktie investono anche nei seguenti asset
